Lakewood-Amedex Biotherapeutics Inc LABT

US Biotechnology

$1.67 ▼ -8.49% ($-0.16)

📉 Near 52W Low ⬇️ Below Yest. Low 🎈 Low Float

Open $1.85

Prev Close $1.83

Day Range $1.63 – $1.85

52W Range $1.66 – $98.20

Market Cap $3.96M

Beta -2.12

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2026-04-23
Shares Out.	1,750,000
Website	lakewoodamedex.com ↗
Phone	19412252515
Revenue	$0
Gross Profit	$0
Net Income	-$3.8M
Total Assets	$5.0M
Total Liabilities	$628,926
Equity	$4.3M

About Lakewood-Amedex Biotherapeutics Inc

Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.

Lakewood-Amedex Biotherapeutics Inc is a publicly traded company under the ticker symbol LABT on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.